Literature DB >> 28264884

Functional and structural insight into properdin control of complement alternative pathway amplification.

Dennis V Pedersen1, Lubka Roumenina2,3,4, Rasmus K Jensen1, Trine Af Gadeberg1, Chiara Marinozzi5, Capucine Picard6, Tania Rybkine2,3,4, Steffen Thiel7, Uffe Bs Sørensen7, Cordula Stover8, Veronique Fremeaux-Bacchi2,3,4,5, Gregers R Andersen9.   

Abstract

Properdin (FP) is an essential positive regulator of the complement alternative pathway (AP) providing stabilization of the C3 and C5 convertases, but its oligomeric nature challenges structural analysis. We describe here a novel FP deficiency (E244K) caused by a single point mutation which results in a very low level of AP activity. Recombinant FP E244K is monomeric, fails to support bacteriolysis, and binds weakly to C3 products. We compare this to a monomeric unit excised from oligomeric FP, which is also dysfunctional in bacteriolysis but binds the AP proconvertase, C3 convertase, C3 products and partially stabilizes the convertase. The crystal structure of such a FP-convertase complex suggests that the major contact between FP and the AP convertase is mediated by a single FP thrombospondin repeat and a small region in C3b. Small angle X-ray scattering indicates that FP E244K is trapped in a compact conformation preventing its oligomerization. Our studies demonstrate an essential role of FP oligomerization in vivo while our monomers enable detailed structural insight paving the way for novel modulators of complement.
© 2017 The Authors.

Entities:  

Keywords:  alternative pathway; complement; deficiency; properdin; structure

Mesh:

Substances:

Year:  2017        PMID: 28264884      PMCID: PMC5391138          DOI: 10.15252/embj.201696173

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

Review 1.  Properdin deficiency: molecular basis and disease association.

Authors:  C A Fijen; R van den Bogaard; M Schipper; M Mannens; M Schlesinger; F G Nordin; J Dankert; M R Daha; A G Sjöholm; L Truedsson; E J Kuijper
Journal:  Mol Immunol       Date:  1999 Sep-Oct       Impact factor: 4.407

2.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

Review 3.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

4.  Structures of complement component C3 provide insights into the function and evolution of immunity.

Authors:  Bert J C Janssen; Eric G Huizinga; Hans C A Raaijmakers; Anja Roos; Mohamed R Daha; Kristina Nilsson-Ekdahl; Bo Nilsson; Piet Gros
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

5.  Mapping of the properdin-binding site in the third component of complement.

Authors:  J D Lambris; J Alsenz; T F Schulz; M P Dierich
Journal:  Biochem J       Date:  1984-01-01       Impact factor: 3.857

6.  Expression and characterisation of the thrombospondin type I repeats of human properdin.

Authors:  M V Perdikoulis; U Kishore; K B Reid
Journal:  Biochim Biophys Acta       Date:  2001-08-13

7.  Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.

Authors:  Takashi Miwa; Sayaka Sato; Damodar Gullipalli; Masaomi Nangaku; Wen-Chao Song
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis.

Authors:  Claudia Kemper; Lynne M Mitchell; Lijuan Zhang; Dennis E Hourcade
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-25       Impact factor: 11.205

10.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more
  27 in total

1.  Crystallization and X-ray analysis of monodisperse human properdin.

Authors:  Dennis Vestergaard Pedersen; Margot Revel; Trine Amalie Fogh Gadeberg; Gregers Rom Andersen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2019-01-23       Impact factor: 1.056

Review 2.  How novel structures inform understanding of complement function.

Authors:  Elena Goicoechea de Jorge; Hugo Yebenes; Marina Serna; Agustín Tortajada; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  Semin Immunopathol       Date:  2017-08-14       Impact factor: 9.623

3.  Functional and structural insight into properdin control of complement alternative pathway amplification.

Authors:  Dennis V Pedersen; Lubka Roumenina; Rasmus K Jensen; Trine Af Gadeberg; Chiara Marinozzi; Capucine Picard; Tania Rybkine; Steffen Thiel; Uffe Bs Sørensen; Cordula Stover; Veronique Fremeaux-Bacchi; Gregers R Andersen
Journal:  EMBO J       Date:  2017-03-06       Impact factor: 11.598

4.  A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.

Authors:  Rasmus K Jensen; Rasmus Pihl; Trine A F Gadeberg; Jan K Jensen; Kasper R Andersen; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2018-03-01       Impact factor: 5.157

Review 5.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

6.  P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner.

Authors:  Nicolas S Merle; Romain Paule; Juliette Leon; Marie Daugan; Tania Robe-Rybkine; Victoria Poillerat; Carine Torset; Véronique Frémeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-08       Impact factor: 11.205

7.  A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.

Authors:  Henrik Pedersen; Rasmus K Jensen; Annette G Hansen; Trine A F Gadeberg; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2020-05-06       Impact factor: 5.157

Review 8.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

9.  The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome.

Authors:  Eliza Ruben; William Planer; Mathivanan Chinnaraj; Zhiwei Chen; Xiaobing Zuo; Vittorio Pengo; Vincenzo De Filippis; Ravi K Alluri; Keith R McCrae; Paolo Macor; Francesco Tedesco; Nicola Pozzi
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

10.  Integrated beamline control and data acquisition for small-angle X-ray scattering at the P12 BioSAXS beamline at PETRAIII storage ring DESY.

Authors:  Nelly R Hajizadeh; Daniel Franke; Dmitri I Svergun
Journal:  J Synchrotron Radiat       Date:  2018-04-25       Impact factor: 2.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.